| Not yet recruiting | 2 | 135 | NA | 3BNC117-LS, 10-1074-LS, Placebo for 3BNC117-LS, Placebo for 10-1074-LS | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1-infection | 02/29 | 02/29 | | |
NCT05383742: Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis |
|
|
| Recruiting | 2 | 330 | RoW | Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD), Pyrazinamide (PZA), ethambutol (EMB), Rifampicin, Isoniazid | National Institute of Allergy and Infectious Diseases (NIAID) | Tuberculous Meningitis | 05/27 | 05/27 | | |
